Medication may provide some benefit for older adults with anxiety disorder

January 21, 2009

Preliminary research suggests that use of the drug escitalopram provided some improvement in symptoms for older adults with generalized anxiety disorder, although the overall benefits were diminished because of nonadherence to the drug by some patients, according to a study in the January 21 issue of JAMA.

Generalized anxiety disorder (GAD), one of the most common psychiatric disorders in older adults, is defined by chronic, difficult-to-control worry and anxiety, with related symptoms such as muscle tension, sleep disturbance and fatigue. The prevalence of GAD is as high as 7.3 percent among community-dwelling older adults and even higher among primary care patients. Because the number of older adults in the U.S. is growing and there is a lack of effective treatment, GAD in older adults will become an increasing human and economic burden, according to background information in the article. Selective serotonin reuptake inhibitors (SSRIs) are effective for younger adults with GAD, but little data exist regarding the outcomes of their use by older adults.

Eric J. Lenze, M.D., of Washington University, St. Louis, and colleagues examined the effectiveness, safety, and tolerability of the SSRI escitalopram for the treatment of GAD in older adults. The study included 177 participants age 60 years or older with a diagnosis of GAD, who were randomized to receive either 10 to 20 mg/d of escitalopram (n = 85) or matching placebo (n = 92) for 12 weeks. Anxiety and other outcomes were measured using a number of assessment tools.

The researchers found that the cumulative incidence of response to treatment was higher in the escitalopram group than in the placebo group (69 percent vs. 51 percent). Participants treated with escitalopram showed greater improvement than with placebo in anxiety symptoms and role functioning, activity limitations and impairments in role and social functioning.

In the intention-to-treat (ITT) analysis, which included those who began the trial but may have dropped out, the response was not different between groups. Of the participants who received escitalopram, 16 (18.5 percent) dropped out of the study before week 12; of the participants who received placebo, 17 (18.4 percent) dropped out before week 12.

Adverse effects of escitalopram were fatigue or sleepiness, sleep disturbance and urinary symptoms.

"The lack of efficacy of escitalopram in the ITT analysis is consistent with its overall modest efficacy, diminished further by nonadherence. Given that patients with anxiety disorders are often poorly adherent to pharmacotherapy, these negative results may more accurately portray the results of treatment in clinical settings," the authors write.

"It is important for clinicians to emphasize to their anxious older patients the need for an adequate trial in which to observe any benefits, as well as the expectation and nature of adverse effects. Given the high human and economic burden of GAD, these data should provide impetus to detect and treat this common disorder. Further study is required to assess efficacy and safety over longer treatment durations."

JAMA and Archives Journals

---

---

	The Essential Guide to Prescription Drugs, Update on Antidepressants, Focus on Lexapro (escitalopram) by The Medicine Information Institute Wondering when this medicine will start to go to work? Worried about possible side effects? Can drug interactions cloud the horizon? What help could herbal medicines be? The Essential Guide to Prescription Drugs helps answer all of these important questions, talks about how to tell if the medicine is starting to work and how to follow up if things seem to be going in the wrong direction. Includes cautions to take while you are on Lexapro, things to talk to youer doctor about before taking it and even tests and helpful web sites that may make things easier to understand.
	Escitalopram: Webster's Timeline History, 2000 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Escitalopram," including when used in literature (e.g. all authors that might have Escitalopram in their name). As such, this book represents the largest compilation of timeline events associated with Escitalopram when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...
	Escitalopram and Depression (Pocket Pharma) by S.A. Montgomery (Author)
	Escitalopram beats paroxetine for generalized anxiety disorder.(Mental Health): An article from: Family Practice News by Damian McNamara (Author) This digital document is an article from Family Practice News, published by International Medical News Group on December 1, 2004. The length of the article is 1170 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Escitalopram beats paroxetine for generalized anxiety disorder.(Mental Health) Author: Damian McNamara Publication: Family Practice News (Magazine/Journal) Date: December 1, 2004 Publisher: International Medical News Group Volume: 34 Issue: 23 Page: 42(1) Distributed by Thomson...
	Escitalopram effective for long-term treatment of GAD.(Adult Psychiatry)(generalized anxiety disorder ): An article from: Clinical Psychiatry News by Robert Finn (Author) This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on September 1, 2004. The length of the article is 1414 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Escitalopram effective for long-term treatment of GAD.(Adult Psychiatry)(generalized anxiety disorder ) Author: Robert Finn Publication: Clinical Psychiatry News (Magazine/Journal) Date: September 1, 2004 Publisher: International Medical News Group Volume: 32 Issue: 9 Page: 42(1) Distributed by Thomson...
	Escitalopram Tx leads to remission in GAD. (Three 8-Week Studies).(generalized anxiety disorder): An article from: Clinical Psychiatry News by Bruce Sylvester (Author) This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on April 1, 2003. The length of the article is 696 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Escitalopram Tx leads to remission in GAD. (Three 8-Week Studies).(generalized anxiety disorder) Author: Bruce Sylvester Publication: Clinical Psychiatry News (Magazine/Journal) Date: April 1, 2003 Publisher: International Medical News Group Volume: 31 Issue: 4 Page: 25(1) Distributed by Thomson...
	Consider escitalopram first for severe major depression. (Most Selective SSRI to Date).: An article from: Clinical Psychiatry News by Carl Sherman (Author) This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on April 1, 2003. The length of the article is 1663 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Consider escitalopram first for severe major depression. (Most Selective SSRI to Date). Author: Carl Sherman Publication: Clinical Psychiatry News (Magazine/Journal) Date: April 1, 2003 Publisher: International Medical News Group Volume: 31 Issue: 4 Page: 25(1) Distributed by Thomson...
	Escitalopram effective, well tolerated depression Tx in primary care setting. (Randomized Controlled Trial).: An article from: Clinical Psychiatry News by Carl Sherman (Author) This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on April 1, 2003. The length of the article is 427 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Escitalopram effective, well tolerated depression Tx in primary care setting. (Randomized Controlled Trial). Author: Carl Sherman Publication: Clinical Psychiatry News (Magazine/Journal) Date: April 1, 2003 Publisher: International Medical News Group Volume: 31 Issue: 4 Page: 25(1) Distributed by Thomson...
	Try mirtazapine or escitalopram for speedy onset: small data sets cited.(Psychopharmacology): An article from: Clinical Psychiatry News by Sherry Boschert (Author) This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on August 1, 2003. The length of the article is 623 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Try mirtazapine or escitalopram for speedy onset: small data sets cited.(Psychopharmacology) Author: Sherry Boschert Publication: Clinical Psychiatry News (Magazine/Journal) Date: August 1, 2003 Publisher: International Medical News Group Volume: 31 Issue: 8 Page: 26(1) Distributed by Thomson...
	Approvals near for new antidepressant therapies. (Duloxetine, Escitalopram).: An article from: Internal Medicine News by Sherry Boschert (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on October 15, 2002. The length of the article is 1095 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Approvals near for new antidepressant therapies. (Duloxetine, Escitalopram). Author: Sherry Boschert Publication: Internal Medicine News (Magazine/Journal) Date: October 15, 2002 Publisher: International Medical News Group Volume: 35 Issue: 20 Page: 46(1) Distributed by Thomson...